MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases. The company generates its pipeline of product candidates from its proprietary suite of next-generation antibody-based technology platforms. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies.
EVENTS & PRESENTATIONS
Dec 8, 2018 12:00 AM EST
Poster presented at 2018 San Antonio Breast Cancer Symposium
Dec 2, 2018 9:00 AM PST
Presentations at 60th Annual ASH Meeting regarding Flotetuzumab (CD123 x CD3 DART Molecule):